UNSPSC 51142552: Lazabemide hydrochloride

This classification denotes a monoamine oxidase inhibitor C8H10ClN3O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PI150J9ZX1, chemically known as 2-pyridinecarboxamide, n-(2-aminoethyl)-5-chloro-, monohydrochloride, but more generally known as lazabemide hydrochloride, which bears US NIH Compound Identifier 163727. Most nations, for tariff and trade purposes, schedule lazabemide hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, LAZABEMIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity.

Lazabemide hydrochloride bears US NLM identifiers UMLS ID C2825397 and NCI Concept Code C80968. SMILES: C1CC(NCC1CL)C(=O)NCCN.CL.

UNSPSC 51142552 Lazabemide hydrochloride is a Commodity code nominally addressing a specific pharmaceutical active ingredient, but recent state and local procurement activity under this code shows little direct alignment with lazabemide itself. The code appears in solicitations for naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products distributed through cooperative purchasing frameworks, and exploratory requests for information on direct-to-manufacturer prescription programs. The issuing bodies are diverse: Seminole County, Florida (a county health department); the Texas Health and Human Services Commission (a state agency); and the Minnesota Multistate Cooperative Purchasing Alliance (a multi-state cooperative administered through Minnesota's Department of Administration). The work being solicited ranges from commodity pharmaceutical procurement through established wholesale channels to strategic vendor capability assessment for alternative distribution models, reflecting the breadth of state and local pharmaceutical supply-chain contracting rather than procurement of a single active pharmaceutical ingredient.

Recent opportunities span Florida, Texas, and Minnesota-led multi-state cooperative membership. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, response due July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota and Oregon through the Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products through designated wholesalers, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. The code shows limited recent activity specifically targeting lazabemide hydrochloride; procurement under this code reflects broader state and local acquisition of pharmaceutical products and services through multiple supply models rather than specialized demand for this particular active ingredient.